|
RSV Vaccine Effectiveness in Immunocompromised Recipients
|
|
Does immunocompromise lower the effectiveness of respiratory syncytial virus (RSV)? A new study published in the Journal of the American Medical Association came up with a multipart answer suggesting that reduced effectiveness could be a problem for some recipients. Vaccines with adjuvants appeared to be more effective in the immunocompromised cohort, however, according to the researchers. Read more.
|
|
|
Continued Use of Some Beta-Blockers Dangerous for Transplant Recipients
|
|
|
A new study presents a strong case that patients on certain types of beta-blockers, primarily nonselective beta-blockers, should discontinue them before undergoing hematopoietic cell transplant for conditions such as leukemia. The drugs, prescribed for cardiovascular issues, could be deadly because they suppress signals from nerves that promote bone marrow regeneration. Find out when they need to be discontinued or changed.
|
|
What Works Best for Anticoagulation in COVID-19 Inpatients?
|
|
|
Almost from the beginning of the COVID-19 pandemic, anticoagulation among hospitalized patients has been a complex issue. A new analysis published in the Annals of Internal Medicine concluded that therapeutic-dose anticoagulation compared with prophylactic-dose anticoagulation reduced 28-day mortality. The evidence also suggests that mortality might be higher with therapeutic-dose anticoagulation compared with intermediate-dose anticoagulation. Read more.
|
|
|
Oral Migraine Drug Appears to Begin Working Quickly
|
|
A new review looks at three new trials on the migraine medication atogepant and reports some promising news: Positive effects appear to begin quickly, with some patients benefiting on Day 1. Find out what the study reports about the improvement in both efficacy and functional outcomes in the first 4 weeks of treatment for the prevention of migraine.
|
|
.jpg)
